

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST

ENTRY  
20.68

SESSION  
483.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-0.65

-1.92

FILE 'REGISTRY' ENTERED AT 10:12:39 ON 29 AUG 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 AUG 2003 HIGHEST RN 574700-05-3  
DICTIONARY FILE UPDATES: 27 AUG 2003 HIGHEST RN 574700-05-3

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP  
PROPERTIES for more information. See STNote 27, Searching Properties  
in the CAS Registry File, for complete details:  
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> e topiramate/cn 5

E1	1	TOPILENE J 700/CN
E2	1	TOPIOSOMERASE I/CN
E3	1 -->	TOPIRAMATE/CN
E4	1	TOPISOLON/CN
E5	1	TOPITRACIN/CN


Searched by: Mary Hale 308-4258 CM-1 1E01

Spwac  
99746

=> s e3;d ide can  
L1 1 TOPIRAMATE/CN

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS on STN  
RN 97240-79-4 REGISTRY  
CN .beta.-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate  
(9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, .beta.-D-fructopyranose deriv.  
OTHER NAMES:  
CN 2,3:4,5-Bis-O-(1-methylethylidene) .beta.-D-fructopyranose sulfamate  
CN McN 4853  
CN RWJ 17021  
CN Topamax  
CN **Topiramate**  
CN Topomax  
FS STEREOSEARCH  
MF C12 H21 N O8 S  
CI COM  
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,  
CEN, CHEMCATS, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU,  
DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*,  
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: WHO

Absolute stereochemistry. Rotation (-).



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

390 REFERENCES IN FILE CA (1937 TO DATE)  
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
391 REFERENCES IN FILE CAPLUS (1937 TO DATE)

REFERENCE 1: 139:154910  
REFERENCE 2: 139:143768  
REFERENCE 3: 139:127103  
REFERENCE 4: 139:111531

Searched by: Mary Hale 308-4258 CM-1 1E01

REFERENCE 5: 139:111529  
REFERENCE 6: 139:110931  
REFERENCE 7: 139:110821  
REFERENCE 8: 139:106468  
REFERENCE 9: 139:98799  
REFERENCE 10: 139:95483

=> fil medl,hcaplus,biosis,embase,wpids  
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.91	490.74

	SINCE FILE ENTRY	TOTAL SESSION
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-1.92

FILE 'MEDLINE' ENTERED AT 10:13:36 ON 29 AUG 2003

FILE 'HCAPLUS' ENTERED AT 10:13:36 ON 29 AUG 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:13:36 ON 29 AUG 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 10:13:36 ON 29 AUG 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:13:36 ON 29 AUG 2003  
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s (l1 or topiramate or topamax) and (wound heal? or fracture heal? or cicatrix  
or granulat? tissue or neurogen? disorder? or impulse disorder?)

L2 0 FILE MEDLINE  
L3 5 FILE HCAPLUS  
L4 0 FILE BIOSIS  
L5 0 FILE EMBASE  
L6 7 FILE WPIDS

TOTAL FOR ALL FILES

L7 12 (L1 OR TOPIRAMATE OR TOPAMAX) AND (WOUND HEAL? OR FRACTURE HEAL?  
OR CICATRIX OR GRANULAT? TISSUE OR NEUROGEN? DISORDER? OR IMPUL  
SE DISORDER?)

=> s l7 and (shapira, n? or shapira n? or lessig, m? or lessig m?)/au,in  
'IN' IS NOT A VALID FIELD CODE

L8 0 FILE MEDLINE  
L9 1 FILE HCAPLUS  
L10 0 FILE BIOSIS  
'IN' IS NOT A VALID FIELD CODE  
L11 0 FILE EMBASE  
L12 1 FILE WPIDS

TOTAL FOR ALL FILES

L13 2 L7 AND (SHAPIRA, N? OR SHAPIRA N? OR LESSIG, M? OR LESSIG M?)/AU  
,IN

=> dup rem l13

PROCESSING COMPLETED FOR L13

L14 1 DUP REM L13 (1 DUPLICATE REMOVED)

=> d cbib abs;s l7 not l13

L14 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

2002:428714 Document No. 136:395995 **Topiramate** and other compounds

for the treatment of **neurogenetic disorders**, impulse  
control disorders, and **wound healing**. **Shapira,**

**Nathan Andrew;** Lessig, Mary Catherine; Driscoll, Daniel John

(University of Florida, USA). PCT Int. Appl. WO 2002043731 A2 20020606,

48 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR,

BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB,

GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,

LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF,

BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU,

MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.

APPLICATION: WO 2001-US44923 20011130. PRIORITY: US 2000-PV250113

20001130.

AB Methods and compns. are provided for the treatment of **neurogenetic disorders**, particularly DSM-IV impulse control disorders such as intermittent explosive disorder, kleptomania, pyromania, pathol. gambling, trichotillomania, and other impulse control disorders such as compulsive buying and problematic Internet use. In a preferred embodiment, the invention provides methods for treating or controlling symptoms assocd. with e.g. attention deficit-hyperactivity disorder, comprising the administration of therapeutically effective amts. of compns. contg. compds. of the invention. In another embodiment, the invention provides methods of promoting **wound healing**, comprising the administration of a therapeutically effective amt. of a compn. comprising the compds. of the invention. Compns. may administered to a wound site via a salve, ointment, or as a component of a bandage or bioadhesive applied to the site of injury. The invention also provides therapeutically effective compns. comprising one or more of the compds. of the invention. The effects of **topiramate** on e.g. impulsivity and cognitive functioning is presented.

*inventive  
entity*

L15 0 FILE MEDLINE

L16 4 FILE HCAPLUS

L17 0 FILE BIOSIS

L18 0 FILE EMBASE

L19 6 FILE WPIDS

TOTAL FOR ALL FILES

L20 10 L7 NOT L13

=> dup rem l20

PROCESSING COMPLETED FOR L20

L21 8 DUP REM L20 (2 DUPLICATES REMOVED)

=> d cbib abs l-8;s (shapira, n? or shapira n?)/au,in and (lessig, m? or lessig m?)/au,in

Searched by: Mary Hale 308-4258 CM-1 1E01

L21 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 1

2003:320036 Document No. 138:338498 Preparation of human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions. Natarajan, Sesha I.; Bastos, Margarita M.; Bernatowicz, Michael S.; Mapelli, Claudio; Lee, Ving; Ewing, William R. (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2003033671 A2 20030424, 153 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2002-US33386 20021018. PRIORITY: US 2001-PV342015 20011018.

AB The invention provides novel human glucagon-like peptide-1 (GLP-1) peptide mimics A-Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Y-Z-B [Xaa1-Xaa9 are naturally or non-naturally occurring amino acid residues; Y and Z are amino acid residues which may be substituted; A and B are optionally present; A is H, an amino acid or peptide contg. approx. 1-15 amino acid residues, an R group [H, (cyclo)alkyl, cycloalkylalkyl, heterocyclyl, heterocycloalkyl, (hetero)aryl, arylalkyl, aryloxyalkyl, heteroarylalkyl, or heteroaryloxyalkyl], an RCO (amide) group, a carbamate group, a urea, a sulfonamido, or an aminosulfonyl group; B is OH, alkoxy, etc., an amino or amino acid residue, or a peptide contg. from 1-15 amino acid residues, terminating at the C-terminus as a carboxamide, ester, carboxyl, or an amino alc.] that mimic the biol. activity of the native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders assocd. with GLP activity. These chem.-modified peptides stimulate insulin secretion in type II diabetics and produce other beneficial insulintropic responses, while exhibiting increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. A method of prepg. the polypeptides comprises replacing the message sequence of the polypeptide with a variant message sequence capable of inducing receptor mediated signal transduction. An example is claimed peptide H-AEGTFTSD-Bip(2-Et)-Bip(2-Me)-NH2 (Bip = biphenylalanine residue).

L21 ANSWER 2 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2003-332915 [31] WPIDS

AB WO2003020737 A UPAB: 20030516

NOVELTY - O-Pyrazole glucoside derivatives (I), their prodrug esters, salts and stereoisomers, are new.

DETAILED DESCRIPTION - O-Pyrazole glucoside derivatives of formula (I), their prodrug esters, salts and stereoisomers, are new:

A = CH<sub>2</sub> or (CH<sub>2</sub>)<sub>2</sub>;

R<sub>1</sub> = H, (aryl)alkyl or alkenyl;

R<sub>2</sub> = (perfluoro)alkyl;

R<sub>3</sub>, R<sub>4</sub> = H, OH, OR<sub>5</sub>, O-aryl, OCH<sub>2</sub>aryl, (cyclo)alkyl, CF<sub>3</sub>, -OCHF<sub>2</sub>, -3,4-(OCH<sub>2</sub>O), -OCF<sub>3</sub>, halogen, -CN, -CO<sub>2</sub>R<sub>5a</sub>, -CO<sub>2</sub>H, -COR<sub>6</sub>, -CH(OH)R<sub>6a</sub>, -CH(OR<sub>5b</sub>)R<sub>6b</sub>, -CONR<sub>6c</sub>R<sub>6d</sub>, -NHCOR<sub>5c</sub>, -NHSO<sub>2</sub>R<sub>5d</sub>, -NHSO<sub>2</sub>aryl, aryl, -SR<sub>5e</sub>, -SOR<sub>5f</sub>, -SO<sub>2</sub>R<sub>5g</sub>, -SO<sub>2</sub>aryl or 5-7 membered heterocycle (optionally containing 1 - 4 heteroatoms of N, O, S, SO and/or SO<sub>2</sub>);

R<sub>3</sub>+R<sub>4</sub> = annelated 5-7 membered carbocycle or heterocycle (optionally containing 1 - 4 heteroatoms of N, O, S, SO and/or SO<sub>2</sub>);

R<sub>5</sub>, R<sub>5a</sub>-R<sub>5g</sub> = alkyl;

R<sub>6</sub>, R<sub>6a</sub>-R<sub>6d</sub> = H, (aryl)alkyl, aryl or cycloalkyl; and

NR<sub>6c</sub>+R<sub>6d</sub> = annelated 5-7 membered heterocycle (optionally containing

1 - 4 heteroatoms of N, O, S, SO and/or SO<sub>2</sub>).

AN INDEPENDENT CLAIM is also included for a pharmaceutical composition comprising (I) and a carrier, or at least one therapeutic agent (a) selected from antidiabetic agent, anti-obesity agent, anti-hypertensive agent, anti-atherosclerotic agent or lipid-lowering agent.

ACTIVITY - Antidiabetic; Ophthalmological; Neuroprotective; Nephrotropic; Vulnerary; Antilipemic; Hypotensive; Antiarteriosclerosis; Anorectic; Vasotropic; Antihyperglycemic.

MECHANISM OF ACTION - Inhibitor of sodium dependent glucose transporters found in the intestine and kidney (SGLT2).

Test details are described, but no results are given.


USE - For treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, Syndrome X, diabetic complications, elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, atherosclerosis, and hypertension (claimed), hypercholesterolemia and tissue ischemia.

ADVANTAGE - (I) Are inhibitors of sodium dependent glucose transporters found in the intestine and kidney (SGLT2) and increase the blood levels of high density lipoprotein (HDL). The composition provides antihyperglycemic results greater than that possible from each component alone.

Dwg.0/0

L21 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN DUPLICATE 2  
2002:813874 Document No. 137:311199 Amino acid complexes of C-aryl glucosides for treatment of diabetes. Gougoutas, Jack Z. (Bristol-Myers Squibb Company, USA). PCT Int. Appl. WO 2002083066 A2 20021024, 80 pp.  
DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2.  
APPLICATION: WO 2002-US11066 20020408. PRIORITY: US 2001-PV283097 20010411.

GI




AB Cryst. complexes are obtained from 1:1 or 2:1 mixts. of either the (D) or (L) enantiomer of natural amino acids and compds. of formula I [R<sub>1</sub>, R<sub>2</sub>, R<sub>2a</sub> = H, OH, OR<sub>5</sub>, alkyl, OCHF<sub>2</sub>, OCF<sub>3</sub>, SR<sub>5a</sub>, halogen; R<sub>3</sub>, R<sub>4</sub> = H, OH, OR<sub>5b</sub>, alkyl, cycloalkyl, CF<sub>3</sub>, OCHF<sub>2</sub>, OCF<sub>3</sub>, halogen, CONR<sub>6</sub>R<sub>6a</sub>, CO<sub>2</sub>R<sub>5c</sub>, CO<sub>2</sub>H, COR<sub>6b</sub>, CH(OH)R<sub>6c</sub>, CH(OR<sub>5d</sub>)R<sub>6d</sub>, CN, NHCOR<sub>5e</sub>, NHSO<sub>2</sub>R<sub>5f</sub>, NHSO<sub>2</sub>-aryl, SR<sub>5g</sub>,

Searched by: Mary Hale 308-4258 CM-1 1E01

SOR5h, SO2R5i, or a five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms (N, O, S, SO, and/or S<sub>2</sub>), or R3 and R4 together with the carbons to which they are attached form an annelated five, six or seven membered carbocycle or heterocycle which may contain 1 to 4 heteroatoms in the ring; R5, R5a-R5i are independently alkyl; R6, R6a-R6d are independently H, alkyl, aryl, alkylaryl or cycloalkyl, or NR6R6a form an annelated five, six or seven membered heterocycle which may contain 1 to 4 heteroatoms in the ring]. A method is also provided for treating diabetes and related diseases employing an SGLT2 (sodium dependent glucose transporters found in the intestine and kidney) inhibiting amt. of the above complex alone or in combination with another antidiabetic agent or other therapeutic agent. Thus, I (R1 = 4-Me, R4 = 4-OCHF<sub>2</sub>, R2, R2a, R3 = H) was prepd. by a multistep procedure starting from o-toluic acid, anisole, 2,3,4,6-tetra-O-benzyl-.beta.-D-glucolactone, and CHF<sub>2</sub>Cl and treated with L-phenylalanine to form the cryst. 1:1 complex.

L21 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN  
 2002:736927 Document No. 137:247879 Preparation of antidiabetic agents C-aryl glucoside as human SGLT2 inhibitors. Ellsworth, Bruce; Washburn, William N.; Sher, Philip M.; Wu, Gang; Meng, Wei (USA). U.S. Pat. Appl. Publ. US 2002137903 A1 20020926, 17 pp., Cont.-in-part of U.S. 6,414,126. (English). CODEN: USXXCO. APPLICATION: US 2002-151436 20020520. PRIORITY: US 1999-PV158773 19991012; US 2000-PV194615 20000405; US 2000-679027 20001004.

GI



I

AB An SGLT2 inhibiting compd. is provided having the formula I method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amt. of the above compd. alone or in combination with another antidiabetic agent or other therapeutic agent (no data). 1A pharmaceutical combination comprising an SGLT2 inhibitor compd. and an antidiabetic agent other than an SGLT2 inhibitor, for treating the complications of diabetes, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent, and/or a lipid-lowering agent (no data). A method for treating or delaying the progression or onset of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed **wound healing**, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high d. lipoprotein levels, which comprises administering to a mammalian species in need of treatment a therapeutically effective amt. of a compd (no data).

L21 ANSWER 5 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN  
 AN 2001-648545 [74] WPIDS  
 AB WO 200174835 A UPAB: 20020626

Searched by: Mary Hale 308-4258 CM-1 1E01

NOVELTY - O-glucosylated benzamide derivatives, their salt, stereoisomers or prodrug esters are new.

DETAILED DESCRIPTION - O-glucosylated benzamide derivatives of formula (I), their salts, stereoisomers or prodrug are new.

n = 0 - 2;

A = phenyl or heteroaryl (containing 1-4 N, O, S, SO and/or SO<sub>2</sub> (both substituted by R<sub>3</sub> and R<sub>4</sub>);

R<sub>1</sub> = H, OR<sub>5</sub>, lower alkyl, aryl, arylalkyl, NHCOR<sub>5</sub>, NR<sub>6</sub>R<sub>6a</sub> or halo;

R<sub>2</sub> = H, OH, OR<sub>5a</sub> or lower alkyl;

R<sub>3</sub> and R<sub>4</sub> = H, OH, OR<sub>5b</sub>, Oaryl, OCH<sub>2</sub>aryl, lower alkyl, cycloalkyl, aryl, arylalkyl, CF<sub>3</sub>, -SCF<sub>3</sub>, -OCHF<sub>2</sub>, -OCF<sub>3</sub>, halo, -CN, -CO<sub>2</sub>R<sub>5c</sub>, -CO<sub>2</sub>H, -CONR<sub>6b</sub>R<sub>6c</sub>, -NR<sub>6d</sub>R<sub>6e</sub>, -SO<sub>2</sub>NH<sub>2</sub>, -NHCOR<sub>5d</sub>, -NHSO<sub>2</sub>R<sub>5e</sub>, -NHSO<sub>2</sub>aryl, -SR<sub>5f</sub>, -SOR<sub>5g</sub>, -SO<sub>2</sub>R<sub>5h</sub>, -SO<sub>2</sub>aryl, -OCH<sub>2</sub>CO<sub>2</sub>R<sub>5i</sub>, -OCH<sub>2</sub>CO<sub>2</sub>H, -OCH<sub>2</sub>CONR<sub>6f</sub>R<sub>6g</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NR<sub>6h</sub>R<sub>6i</sub>, 5-7 membered heterocycle containing 1-4 N, O, S, SO and/or SO<sub>2</sub>;

R<sub>3</sub>+R<sub>4</sub> = 5-7 membered carbocycle or heterocycle containing 1-4 N, O, S, SO and/or SO<sub>2</sub>;

R<sub>5</sub> and R<sub>5a</sub> - R<sub>5i</sub> = lower alkyl;

R<sub>6</sub> and R<sub>6a</sub> - R<sub>6i</sub> = H, alkyl, aryl, arylalkyl or cycloalkyl.

With the proviso when A is phenyl substituted by R<sub>3</sub> and R<sub>4</sub>, then n is 1, and when R<sub>2</sub> is alkoxy, then R<sub>1</sub> cannot be alkoxy.

INDEPENDENT CLAIMS are included for the following:

(1) a pharmaceutical combination (C1) comprising (I) and an antidiabetic agent (II) other than (I), an anti-obesity agent (III) and/or a lipid lowering agent (IV); and

(2) a pharmaceutical combination (C2) comprising (I) and (II).

ACTIVITY - Antidiabetic; Ophthalmological; Neuroprotective; Nephrotropic; Vulnerary; Antilipemic; Anorectic; Antiarteriosclerotic; Hypotensive.

MECHANISM OF ACTION - Sodium dependent glucose transporters found in the intestine and kidney (SGLT2) inhibitor.

USE - In the treatment of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, syndrome X, diabetic complications, or elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, atherosclerosis, hypertension and for increasing high density lipoprotein levels (all claimed)

ADVANTAGE - The compounds are safe, orally active without any side effects.

Dwg.0/0

L21 ANSWER 6 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2001-656984 [75] WPIDS

AB WO 200174834 A UPAB: 20020626

NOVELTY - O-aryl glucoside derivatives (I), their salt, stereoisomers or prodrug esters are new.

DETAILED DESCRIPTION - O-aryl glycoside derivatives of formula (I), their salts, stereoisomers or prodrug are new.

Y = phenyl (substituted by R<sub>5</sub> or R<sub>6</sub>) or heteroaryl;

R<sub>1</sub> - R<sub>4</sub> = H, OH, OR<sub>7</sub>, lower alkyl or halo;

R<sub>1</sub> + R<sub>2</sub> or R<sub>2</sub> + R<sub>3</sub> or R<sub>3</sub> + R<sub>4</sub> = 5-7 membered carbocycle or 5-7 membered heterocycle comprising 1-4 O, N, S, SO and/or SO<sub>2</sub>;

R<sub>5</sub>, R<sub>6</sub> = H, OH, OR<sub>7a</sub>, Oaryl, -OCH<sub>2</sub>aryl, lower alkyl, cycloalkyl, aryl, arylalkyl, CF<sub>3</sub>, arylalkenyl, -OCHF<sub>2</sub>, -OCF<sub>3</sub>, halo, -CN, -CO<sub>2</sub>R<sub>7b</sub>, -CO<sub>2</sub>H, -COR<sub>8f</sub>, CHOHR<sub>8g</sub>, CH(OR<sub>7h</sub>)R<sub>8h</sub>, -CONR<sub>8R</sub>8a, -NHCOR<sub>7c</sub>, -NHSO<sub>2</sub>R<sub>7d</sub>, -NHSO<sub>2</sub> aryl, -SR<sub>7e</sub>, -SOR<sub>7f</sub>, -SO<sub>2</sub>R<sub>7g</sub>, -SO<sub>2</sub> aryl, -OCH<sub>2</sub>CO<sub>2</sub>R<sub>7i</sub>, -OCH<sub>2</sub>CO<sub>2</sub>H, -OCH<sub>2</sub>CONR<sub>8b</sub>R<sub>8c</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NR<sub>8d</sub>R<sub>8e</sub> or 5 - 7 membered heterocycle containing 1 - 4 heteroatoms selected from N, O, S, SO and/or SO<sub>2</sub>;

R<sub>5</sub>+R<sub>6</sub> = annealed 5-7 membered carbocycle or heterocycle containing



1-4 heteroatoms selected from N, O, S, SO and/or SO<sub>2</sub>;  
R<sub>7</sub> and R<sub>7a</sub> - R<sub>7i</sub> = lower alkyl;  
R<sub>8</sub> and R<sub>8a</sub> - R<sub>8h</sub> = H, alkyl, aryl, arylalkyl, cycloalkyl; or  
N + R<sub>8</sub> + R<sub>8a</sub> - R<sub>8h</sub> = an annealed 5 - 7 membered heterocycle  
containing 1 - 4 N, O, S, SO and/or SO<sub>2</sub>;  
A = O(CH<sub>2</sub>)<sub>m</sub>, S, NH(CH<sub>2</sub>)<sub>m</sub> or (CH<sub>2</sub>)<sub>n</sub>;  
n = 0 - 3; and  
m = 0 - 2.

Provided that when A is CH<sub>2</sub>, then Y is phenyl substituted by R<sub>5</sub> and R<sub>6</sub>; when R<sub>1</sub> is OH and R<sub>3</sub> is alkyl, then at least one of R<sub>1</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> is non H; when R<sub>2</sub> and R<sub>3</sub> are then at least one of R<sub>1</sub>, R<sub>4</sub>, R<sub>5</sub> and R<sub>6</sub> is non H; when R<sub>2</sub> is methyl, R<sub>5</sub> is OH, and R<sub>6</sub> is alkyl, then at least one of R<sub>1</sub>, R<sub>3</sub> and R<sub>4</sub> is non H; and when R<sub>2</sub> is chlorine, then at least one of R<sub>1</sub> and R<sub>3</sub> - R<sub>6</sub> is non-H.

INDEPENDENT CLAIMS are included for the following:

(1) a pharmaceutical combination (C1) comprising (I) and an antidiabetic agent (II) other than (I), an anti-obesity agent (III) and/or a lipid lowering agent (IV); and

(2) a pharmaceutical combination (C2) comprising (I) and (II).

ACTIVITY - Antidiabetic; Ophthalmological; Neuroprotective; Nephrotropic; Vulnerary; Antilipemic; Anorectic; Antiarteriosclerotic; Hypotensive.

MECHANISM OF ACTION - Sodium dependent glucose transporters found in the intestine and kidney (SGLT2) inhibitor.

USE - In the treatment of diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, **wound healing**, insulin resistance, hyperglycemia, hyperinsulinemia, syndrome X, diabetic complications, or elevated blood levels of free fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, atherosclerosis, hypertension and for increasing high density lipoprotein levels (all claimed)

ADVANTAGE - The compounds are safe, orally active without any side effects.

Dwg. 0/0

L21 ANSWER 7 OF 8 WPIDS COPYRIGHT 2003 THOMSON DERWENT on STN

AN 2001-290705 [30] WPIDS

AB WO 200127128 A UPAB: 20010603

NOVELTY - Compounds (I), their salts, stereoisomers and prodrug esters, are new.

DETAILED DESCRIPTION - Compounds of formula (I), their salts, stereoisomers and prodrug esters, are new.

R<sub>1</sub>, R<sub>2</sub>, R<sub>2a</sub> = H, OH, OR<sub>5</sub>, alkyl, CF<sub>3</sub>, OCHF<sub>2</sub>, OCF<sub>3</sub>, SR<sub>5i</sub> or halo; or  
C + 2 of R<sub>1</sub>, R<sub>2</sub>, R<sub>2a</sub> = 5-7 membered carbo- or heterocycle optionally containing 1-4 N, O, S, SO and/or SO<sub>2</sub>;

R<sub>3</sub>, R<sub>4</sub> = H, OH, OR<sub>5a</sub>, O-aryl, OCH<sub>2</sub>-aryl, alkyl, cycloalkyl, CF<sub>3</sub>, OCHF<sub>2</sub>, OCF<sub>3</sub>, halo, CN, COOR<sub>5b</sub>, COOH, COR<sub>6b</sub>, CH(OH)R<sub>6c</sub>, CH(OR<sub>5h</sub>)R<sub>6d</sub>, CONR<sub>6R6a</sub>, NHCOR<sub>5c</sub>, NHSO<sub>2</sub>R<sub>5d</sub>, NHSO<sub>2</sub>aryl, aryl, SR<sub>5e</sub>, SOR<sub>5f</sub>, SOR<sub>5g</sub>, SO<sub>2</sub>aryl, or 5-7 membered heterocycle optionally containing 1-4 N, O, S, SO and/or SO<sub>2</sub>; or

CR<sub>3</sub>CR<sub>4</sub> = 5-7 membered carbo- or heterocycle optionally containing 1-4 N, O, S, SO and/or SO<sub>2</sub>;

R<sub>5</sub>, R<sub>5a</sub>-R<sub>5i</sub> = alkyl;

R<sub>6</sub>, R<sub>6a</sub>-R<sub>6d</sub> = H, alkyl, aryl, alkylaryl or cycloalkyl; or

NR<sub>6R6a</sub> = 5-7 membered carbo- or heterocycle optionally containing 1-4 N, O, S, SO and/or SO<sub>2</sub>;

A = O, S, NH or (CH<sub>2</sub>)<sub>n</sub>;

n = 0-3;

provided that: (i) when A = O or (CH<sub>2</sub>)<sub>n</sub> and at least one R<sub>1</sub>-R<sub>4</sub> = OH or OR<sub>5</sub>, then at least one R<sub>1</sub>, R<sub>2</sub> or R<sub>2a</sub> = CF<sub>3</sub>, OCF<sub>3</sub> or OCHF<sub>2</sub>, and/or at

least one R3, R4 = CF3, OCHF2, OCF3, CN, COOR5b, CH(OR5h)R6d, CH(OH)R6c, COR6b, NHCOR5c, NHSO2R5d, NHSO2aryl, aryl, SR5e, SOR5f, SO2R5g or SO2aryl.

INDEPENDENT CLAIMS are also included for:

(1) a pharmaceutical composition comprising (I) and an antidiabetic agent other than an SGLT2 inhibitor, an agent for treating the complications of diabetes, an antiobesity agent, an antihypertensive agent, an antiplatelet agent, an antiatherosclerotic agent and/or a lipid-lowering agent; and

(2) intermediate compounds of formula (II) or (III).

Y = H or OH;

X = SnBU3, B(OH)2, Br or a group of formula (i);

provided that for (III), Y = OH only when X = Br.

ACTIVITY - Antidiabetic; anorectic; hypotensive; anticoagulant; antiarteriosclerotic; antilipemic.

MECHANISM OF ACTION - C-aryl glucoside SGLT2 inhibitor.

An assay for SGLT2 activity is described (method of Ryan et. al., Kidney International, (1994), 45, 48-57). No activity data is disclosed.

USE - (I) Are useful for treating or delaying progression or onset of Type II diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, delayed wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, elevated blood levels of fatty acids or glycerol, hyperlipidemia, obesity, hypertriglyceridemia, Syndrome X, diabetic complications, atherosclerosis or hypertension, or for increasing high density lipoprotein levels (all claimed).

Dwg.0/0

L21 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2003 ACS on STN

2000:144772 Document No. 132:189689 Bioreductive conjugates for drug targeting. Adams, Ged; Blake, David; Naughton, Declan; Stratford, Ian (Theramark Limited, UK; Adams, Margaret). PCT Int. Appl. WO 2000010610 A2 20000302, 48 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG. (English). CODEN: PIXXD2. APPLICATION: WO 1999-GB2606 19990819. PRIORITY: GB 1998-18027 19980819; GB 1998-18156 19980820.

AB The use of a bioreductive conjugate comprised of a noncytotoxic bioreductive moiety having linked thereto at least one therapeutic agent, and salts thereof, is disclosed for the healing of wounds and the treatment of fibrotic disorders, ulcerative colitis, inflammatory bowel disease, epilepsy, cardiovascular reperfusion injury, cerebral reperfusion injury, hypertension, cystic fibrosis, psoriasis, para-psoriasis, peptic ulcers, gastric ulcers, duodenal ulcers, diabetic ulcers dementia, oncol., AIDS, rheumatoid arthritis, diabetes, and ischemia. Various specific conjugates for treating these conditions are also disclosed.

'IN' IS NOT A VALID FIELD CODE

L22 3 FILE MEDLINE

L23 1 FILE HCAPLUS

L24 2 FILE BIOSIS

'IN' IS NOT A VALID FIELD CODE

L25 3 FILE EMBASE

L26 1 FILE WPIDS

TOTAL FOR ALL FILES

Searched by: Mary Hale 308-4258 CM-1 1E01

L27 10 (SHAPIRA, N? OR SHAPIRA N?)/AU,IN AND (LESSIG, M? OR LESSIG M?)/AU,IN

=> s l27 not (l7 or l13)

L28 3 FILE MEDLINE  
L29 0 FILE HCAPLUS  
L30 2 FILE BIOSIS  
L31 3 FILE EMBASE  
L32 0 FILE WPIDS

TOTAL FOR ALL FILES

L33 8 L27 NOT (L7 OR L13)

=> dup rem l33

PROCESSING COMPLETED FOR L33

L34 4 DUP REM L33 (4 DUPLICATES REMOVED)

=> d cbib abs 1-4

L34 ANSWER 1 OF 4 MEDLINE on STN DUPLICATE 1  
2003291518 Document Number: 22703115. PubMed ID: 12820176. Problematic internet use: proposed classification and diagnostic criteria. **Shapira Nathan A; Lessig Mary C**; Goldsmith Toby D; Szabo Steven T; Lazoritz Martin; Gold Mark S; Stein Dan J. (Department of Psychiatry, E.f. & W.L. McKnight Brain Institute, University of Florida, Gainesville, Florida 32610-0383, USA.. shapira@psych.ufl.edu) . DEPRESSION AND ANXIETY, (2003) 17 (4) 207-16. Journal code: 9708816. ISSN: 1091-4269. Pub. country: United States. Language: English.  
AB Since the mid-1990s, there have been frequent reports of individuals whose use of the computer and internet is problematic. Given the recent expansion and the expected increase in internet availability and usage in the coming years, it is important that healthcare professionals be informed about this behavior and its associated problems. Recently, psychological and psychiatric literature has described individuals that exhibit problematic internet use who often suffer from other psychiatric disorders. In the face of this comorbidity, it is essential to evaluate whether these individuals represent a distinct class of disorder, or a manifestation/coping mechanism related to other underlying diagnosis. In either event, problematic internet use negatively impacts social and emotional functioning. Based on the current limited empirical evidence, problematic internet use may best be classified as an impulse control disorder. It is therefore imperative that problematic internet use be appropriately identified among symptomatic individuals. For these reasons, we propose specific diagnostic criteria that will allow for consistent identification and assist in further study of this behavior. Copyright 2003 Wiley-Liss, Inc.

L34 ANSWER 2 OF 4 MEDLINE on STN DUPLICATE 2  
2002387645 Document Number: 22131603. PubMed ID: 12135538. Topiramate attenuates self-injurious behaviour in Prader-Willi syndrome. **Shapira Nathan A; Lessig Mary C**; Murphy Tanya K; Driscoll Daniel J; Goodman Wayne K. Int J Neuropsychopharmacol, (2002 Jun) 5 (2) 141-5. Journal code: 9815893. ISSN: 1461-1457. Pub. country: England: United Kingdom. Language: English.  
AB Self-injurious behaviour (SIB), most notably skin picking, has been described by various terms in the literature ranging from neurotic/psychogenic excoriations to compulsive/pathological skin picking. Prader-Willi Syndrome (PWS) is a neurogenetic multisystem disorder characterized by infantile hypotonia, mental retardation, short stature, hypogonadism, dysmorphic features, and hyperphagia with a high risk of

Searched by: Mary Hale 308-4258 CM-1 1E01

obesity. Psychiatric manifestations include SIBs in the form of skin picking, nail biting and rectal gouging. Topiramate is a novel anti-epileptic medication without significant liability of weight gain. There are no published reports of topiramate being utilized in PWS or SIB. We report attenuation of SIB with resultant lesion healing in three PWS adults treated with topiramate in an 8-wk open-label trial. Although our findings should be treated with caution, they suggest that double-blind or cross-over studies with topiramate are warranted to establish the possible role of topiramate in attenuating SIB in PWS and other disorders that involve SIB.

L34 ANSWER 3 OF 4 MEDLINE on STN DUPLICATE 3  
2002037525 Document Number: 21609123. PubMed ID: 11765278. Topiramate for reversing atypical antipsychotic weight gain. Lessig M C; Shapira N A; Murphy T K. JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, (2001 Dec) 40 (12) 1364. Journal code: 8704565. ISSN: 0890-8567. Pub. country: United States. Language: English.

L34 ANSWER 4 OF 4 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN  
2002113227 EMBASE Topiramate for reversing atypical antipsychotic weight gain [2]. Lessig M.C.; Shapira N.A.; Murphy T.K.; M.C. Lessig, Department of Psychiatry, E.F./W.L. McKnight Brain Inst., University of Florida, Gainesville, FL, United States. Journal of the American Academy of Child and Adolescent Psychiatry 40/12 (1364) 2001. Refs: 5. ISSN: 0890-8567. CODEN: JAAPEE. Pub. Country: United States. Language: English.

TI Methods and systems for assessing biological materials using optical and spectroscopic detection techniques

IN Hochman, Daryl W., Seattle, WA, United States

PA Cytoscan Sciences, L.L.C., Seattle, WA, United States (U.S. corporation)

PI US 6319682 B1 20011120

AI US 2000-629046 20000731 (9)

RLI Continuation-in-part of Ser. No. US 1999-326008, filed on 4 Jun 1999, now patented, Pat. No. US 6096510, issued on 1 Aug 2000  
Continuation-in-part of Ser. No. US 1997-949416, filed on 14 Oct 1997, now patented, Pat. No. US 5976825, issued on 2 Nov 1999 Continuation of Ser. No. US 1995-539296, filed on 4 Oct 1995, now patented, Pat. No. US 5902732, issued on 11 May 1999

DT Utility

FS GRANTED

EXNAM Primary Examiner: Leary, Louise N.

LREP Speckman, Ann W.

CLMN Number of Claims: 53

ECL Exemplary Claim: 1

DRWN 49 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 2306

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Optical detection techniques for the assessment of the physiological state, health and/or viability of biological materials are provided. Biological materials which may be examined using such techniques include cells, tissues, organs and subcellular components. The inventive techniques may be employed in high throughput screening of potential diagnostic and/or therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . such as depression, anxiety, bipolar disorder, schizophrenia, Parkinson's disease and other neurodegenerative disorders, inflammation, trauma, malignancies such as cancer, angiogenesis, **wound healing**, immune deficiencies, and the like. Test agents and conditions may also be tested for safety and efficacy for applications such. . .

DETD . . . mephenytoin, paramethadione, phenthenylate, phenacemide, metharbitol, benzchlorpropanamide, phensuximide, primidone, methsuximide, ethotoin, aminogluthetimide, diazepam, clonazepam, clorazepate, fosphenytoin, ethosuximide, valporate, felbamate, gabapentin, lamotrigine, **topiramate**, vigabatrin, tiagabine, zonisamide, clobazam, thiopental, midazolam, propofol, levetiracetam, oxcarbazepine, CCPene, GYK152466 and sumatriptan. As can be readily appreciated, the above-noted. . .

CLM What is claimed is:

. . . sclerosis, psychiatric disorders, depression, anxiety, bipolar disorder, schizophrenia, Parkinson's disease, inflammation, trauma, mechanical injury, anoxia, stroke, ischemia, hypoxia, malignancies, angiogenesis, **wound healing**, and immune deficiencies.

L7 ANSWER 4 OF 4 USPATFULL on STN

AN 1998:98932 USPATFULL

TI DHA-pharmaceutical agent conjugates of taxanes

IN Shashoua, Victor E., Brookline, MA, United States

Swindell, Charles S., Merion, PA, United States

Webb, Nigel L., Bryn Mawr, PA, United States

Bradley, Matthews O., Laytonsville, MD, United States

PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)

PI US 5795909 19980818

AI US 1996-651312 19960522 (8)

DT Utility

FS Granted

EXNAM Primary Examiner: Jarvis, William R. A.

LREP Wolf, Greenfield & Sacks, P.C.

CLMN Number of Claims: 12

ECL Exemplary Claim: 1  
DRWN 27 Drawing Figure(s); 14 Drawing Page(s)  
LN.CNT 2451

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

SUMM . . . of amyotrophic lateral sclerosis; treatment of cerebral ischemia; treatment of Paget's disease; treatment of unstable angina; uricosuric; vasoconstrictor; vasodilator; vulnerary; **wound healing** agent; xanthine oxidase inhibitor.

DETD . . . Phenobarbital; Phenobarbital Sodium; Phensuximide; Phenytoin; Phenytoin Sodium; Primidone; Progabide; Ralitoline; Remacemide Hydrochloride; Ropizine; Sabeluzole; Stiripentol; Sulthiame; Thiopental Sodium; Tiletamine Hydrochloride; **Topiramate**; Trimethadione; Valproate Sodium; Valproic Acid; Vigabatrin; Zoniclezole Hydrochloride; Zonisamide.

DETD **Wound healing** agent: Ersofermin.

DETD . . . synergist; thyroid hormone; thyroid inhibitor; thyromimetic; amyotrophic lateral sclerosis agents; Paget's disease agents; unstable angina agents; uricosuric; vasoconstrictor; vasodilator; vulnerary; **wound healing** agent; xanthine oxidase inhibitor.

=>